Growth Hormone Axis Limited evidence

GHRP-2

Growth hormone releasing peptide 2

Also known as: Pralmorelin, KP-102, GPA-748

In plain language

GHRP-2 is a synthetic peptide that stimulates the pituitary to release growth hormone by acting on the ghrelin receptor. It has been studied as a diagnostic agent for growth hormone deficiency and is used in that role in some countries. Evidence for wellness and performance uses is limited.

What it is explored for

GHRP-2 has more human pharmacology behind it than many secretagogues, reliably prompting the pituitary to release growth hormone, and it is even used as a diagnostic agent for GH deficiency in some countries. That said, controlled trials for muscle, recovery, or anti-aging uses are limited, so the wellness evidence stays early. Here is where interest and reported use are highest.

  • Stimulating natural growth hormone release
  • Growth hormone deficiency testing
  • Appetite and body-composition research
  • Recovery and lean-mass interest
  • Pairing with GHRH analogs

These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.

How it works

GHRP-2 activates the growth hormone secretagogue (ghrelin) receptor, prompting the pituitary to release a pulse of growth hormone and acting synergistically with GHRH.

  • Ghrelin receptor agonism. Stimulates the GHS receptor to trigger growth hormone release.
  • Synergy with GHRH. Combined with a GHRH analog it produces a larger GH pulse than either alone in human pharmacology studies.
  • Secondary hormone effects. Can modestly raise cortisol, prolactin, and appetite, more so than newer selective secretagogues.

Diagnostic GH-release effects are documented in human studies; broader wellness outcomes are not established by controlled trials.

Evidence summary

GHRP-2 has more human pharmacology behind it than many secretagogues, including use as a GH-stimulation test, and it reliably raises growth hormone. However, controlled trials supporting its marketed uses for muscle, recovery, or anti-aging are limited, and effects on appetite and other hormones complicate the picture.

Reported safety & side effects

Short-term studies report it is generally tolerated, with increased appetite, flushing, and modest rises in cortisol and prolactin among the more common effects. Long-term human safety is not established.

Reported commonIncreased appetite, flushing, water retention
Hormonal effectsModest rises in cortisol and prolactin
Human safety dataLimited; no long-term trials

Stacking notes

Full stacking guide
Stacks well with

A GHRH analog plus a growth-hormone-releasing peptide, the classic two-pathway approach to a stronger, more natural GH pulse than either alone.

Sermorelin
Use caution combining

MK-677 already raises growth hormone and IGF-1 strongly on its own. Adding another secretagogue compounds water retention, appetite, and insulin-resistance effects for little clear added benefit.

MK-677Ipamorelin

Stacking two peptides that hit the same ghrelin receptor (for example ipamorelin with GHRP-6 or hexarelin) is largely redundant and increases hunger, cortisol, and prolactin without a clear reason.

IpamorelinGHRP-6

General educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.

Frequently asked

Is GHRP-2 FDA-approved?

No. GHRP-2 is not approved by the FDA. It is approved as a diagnostic agent for growth hormone deficiency in some countries but is sold as a research chemical in the US.

Why does GHRP-2 increase appetite?

It activates the ghrelin receptor, and ghrelin is the body's hunger hormone, so appetite stimulation is an expected effect, more pronounced than with more selective secretagogues like ipamorelin.

Is there strong evidence for muscle gain?

No. While it reliably raises growth hormone, controlled human trials demonstrating meaningful muscle or performance benefits have not been published.